格隆汇1月14日丨东亚药业(605177.SH)公布，经浙江东亚药业股份有限公司财务部门初步测算，预计公 司2025年度归属于上市公司股东的净利润为负值，2025年度经营业绩将出现亏损。 ...

Group 1 - East Asia Pharmaceutical Co., Ltd. experienced a stock price increase of 7.02%, reaching 21.49 CNY per share, with a trading volume of 4.82 million CNY and a turnover rate of 0.20%, resulting in a total market capitalization of 2.465 billion CNY [1] - The company, established on February 6, 1998, and listed on November 25, 2020, specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1] - The main revenue composition includes: β-lactam antibiotics (44.84%), anticholinergic and synthetic antispasmodic drugs (23.92%), quinolone antibiotics (12.86%), antifungal drugs for skin use (8.87%), other products (5.05%), and additional (supplementary) products (4.46%) [1] Group 2 - Noan Fund's Noan Multi-Strategy Mixed A (320016) entered the top ten circulating shareholders of East Asia Pharmaceutical, holding 811,700 shares, which is 0.72% of the circulating shares, with an estimated floating profit of approximately 1.1445 million CNY [2] - The Noan Multi-Strategy Mixed A fund was established on August 9, 2011, with a current scale of 1.855 billion CNY, achieving a year-to-date return of 5.21% and a one-year return of 88.18% [2] - The fund manager, Kong Xianzheng, has a tenure of 5 years and 50 days, with the fund's total asset size at 5.608 billion CNY, achieving a best return of 93.39% and a worst return of -16.74% during his tenure [3]

Group 1 - The stock price of Dongya Pharmaceutical (605177.SH) has dropped to 20.36 yuan, a decline of 3.55%, currently in a state of breaking the issue price [1] - Dongya Pharmaceutical was listed on the Shanghai Stock Exchange on November 25, 2020, with an issue price of 31.13 yuan per share, and the stock price fell below the issue price on February 8, 2021 [1] - The total number of shares issued by Dongya Pharmaceutical was 28.4 million, with a total fundraising amount of 884 million yuan, and a net amount of 782 million yuan after deducting issuance costs [1] Group 2 - The company has been approved to issue 6.9 million convertible bonds, with a total fundraising amount of 69 million yuan, and a net amount of 68.01844 million yuan after deducting issuance costs [2] - The funds raised from the bond issuance were fully in place as of July 12, 2023, and verified by Zhonghui Accounting Firm [2] - Since its listing, the company has raised funds twice, totaling 1.574 billion yuan [3]

Group 1 - East Asia Pharmaceutical's stock price increased by 5.75% on January 8, reaching 19.69 CNY per share, with a trading volume of 28.52 million CNY and a turnover rate of 1.33%, resulting in a total market capitalization of 2.259 billion CNY [1] - The stock has risen for three consecutive days, with a cumulative increase of 4.61% during this period [1] - The company, established on February 6, 1998, and listed on November 25, 2020, specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1] Group 2 - The main revenue composition of East Asia Pharmaceutical includes: β-lactam antibiotics (44.84%), anticholinergic and synthetic antispasmodic drugs (23.92%), quinolone antibiotics (12.86%), antifungal drugs for skin use (8.87%), and other products (5.05%) [1] - Notably, the fund "Nuoan Multi-Strategy Mixed A" (320016) has entered the top ten circulating shareholders of East Asia Pharmaceutical, holding 811,700 shares, which is 0.72% of the circulating shares [2] - The fund has generated a floating profit of approximately 868,600 CNY today, with a floating profit of 665,600 CNY during the three-day increase [2]

证券日报网讯1月5日，东亚药业（605177）在互动平台回答投资者提问时表示，截至2025年12月31日， 公司股东人数为10607户。 ...

| | | 浙江东亚药业股份有限公司 未转股可转债情况：截至 2025 年 12 月 31 日，尚未转股的"东亚转债" 金额为人民币 666,220,000 元，占"东亚转债"发行总量的比例为 96.5536%。 本季度转股情况：2025 年 10 月 1 日至 2025 年 12 月 31 日，共有 1,000 元"东亚转债"转为公司 A 股普通股，转股股数为 49 股。 关于可转债转股结果暨股份变动公告 一、"东亚转债"发行上市概况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经中国证券监督管理委员会证监许可〔2023〕1165 号文核准，浙江东亚药 业股份有限公司（以下简称"公司"）于 2023 年 7 月 6 日发行了 690 万张可转 换公司债券，每张面值 100 元，发行总额 69,000 万元，期限 6 年。 重要内容提示： 经上海证券交易所（以下简称"上交所"）自律监管决定书〔2023〕166 号 文同意，公司发行的 69,000 万元可转换公司债券于 2023 年 8 月 2 日起在上交所 挂牌交易，债券 ...

Group 1 - The core point of the article is that East Asia Pharmaceutical announced that its stock price has been below 90% of the current conversion price for 10 trading days, which may trigger a downward adjustment of the conversion price for its convertible bonds [2] - The specific conversion price mentioned is 18.25 yuan per share, and if the stock price continues to remain below this threshold, the company will hold a board meeting to decide on the adjustment [2] - The company emphasizes the importance of investors being aware of the potential investment risks associated with this situation [2]

| | | 浙江东亚药业股份有限公司 关于"东亚转债"预计满足转股价格修正条件 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至本公告日，浙江东亚药业股份有限公司（以下简称"公司"）股票自 2025 年 12 月 12 日至 2025 年 12 月 30 日已有 10 个交易日的收盘价低于当期转 股价格的 90%（即 18.25 元/股）。若后续公司股票收盘价格继续低于当期转股 价格的 90%，预计将有可能触发转股价格向下修正条件。若触发条件，公司将于 触发条件当日召开董事会审议决定是否修正转股价格，并及时履行信息披露义务。 敬请广大投资者注意投资风险。 一、可转换公司债券发行上市情况 （一）可转债发行情况 经中国证券监督管理委员会《关于同意浙江东亚药业股份有限公司向不特定 对象发行可转换公司债券注册的批复》（证监许可〔2023〕1165 号）同意，公 司于 2023 年 7 月 6 日向不特定对象发行可转换公司债券 6,900,000 张，发行价格 为每张面值 100 元人民币，按面值发行， ...

Group 1 - The fourth meeting of the board of directors of Zhejiang Dongya Pharmaceutical Co., Ltd. was held on December 25, 2025, with all 7 directors present [2][4] - The meeting approved the election of a director to represent the company in executing company affairs and the adjustment of the audit committee members [3][5] - The voting results for both resolutions were unanimous, with 7 votes in favor and no votes against or abstentions [4][6] Group 2 - Non-independent director Wang Sheng submitted his resignation due to adjustments in the company's governance structure, effective immediately upon delivery [9][10] - Wang Sheng was elected as the employee representative director during the employee representative assembly held on the same day, with a term aligned with the current board [9][11] - Wang Sheng holds 23,000 shares directly and 88,235 shares indirectly through an investment partnership, and his resignation does not affect the board's operational capacity [10] Group 3 - The board elected Chairman Chi Cheng as the director representing the company in executing company affairs, effective immediately [14][15] - The audit committee was adjusted to include members Wang Sheng, Feng Yan, and Cui Sunliang, with Feng Yan being appointed as the committee's convener [16][17] - The adjustments to the audit committee are in line with changes in the company's governance structure [16][18]

Group 1 - The core point of the article is that East Asia Pharmaceutical has reported its shareholder count as of December 20, 2025, which stands at 10,415 households [2]